New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
08:05 EDTDYAXDyax announces publication of DX-2930 scientific data
Dyax announced the online publication of scientific data for DX-2930 in two peer-reviewed journals. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. The first paper titled “A Phase 1 Study Investigating DX-2930 in Healthy Subjects” by Chyung et al. was published online in the Annals of Allergy, Asthma and Immunology. These data indicate that DX-2930 has a long half-life in humans and thus the potential for prophylactic inhibition of pKal activity for the therapeutic treatment of HAE. DX-2930 is now being evaluated in a Phase 1b study in patients with HAE. The second paper titled “Inhibition of Plasma Kallikrein by a Highly Specific, Active Site Blocking Antibody” by Kenniston et al. was published online in The Journal of Biological Chemistry. The paper describes the discovery and preclinical evaluation of DX-2930 as a long-acting inhibitor of pKal proteolytic activity. This paper is expected to appear in the September 2014 print issue of the journal. The company said, "These data, combined with data that will be obtained from the ongoing Phase 1b study, will inform and guide the future clinical development of DX-2930.”
News For DYAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2015
11:22 EDTDYAXOptions with decreasing implied volatility
Subscribe for More Information
11:07 EDTDYAXOptions with decreasing implied volatility
Subscribe for More Information
06:08 EDTDYAXDyax 7.4M share Secondary priced at $27.00
Subscribe for More Information
April 7, 2015
11:09 EDTDYAXOptions with decreasing implied volatility
Subscribe for More Information
April 6, 2015
19:27 EDTDYAXOn The Fly: After Hours Movers
Subscribe for More Information
17:29 EDTDYAXDyax sees Q1 KALBITOR net sales $15.6M-$16M
Q1 revenue consensus consensus $21.19M. On Monday, April 6, Dyax filed with the SEC a preliminary prospectus supplement relating to the sale of Dyax’s common stock in a proposed underwritten public offering. In connection with the offering, Dyax disclosed that KALBITOR gross sales for the quarter ended March 31, were approximately $17.6M; subject to final adjustments for gross to net sales data, net sales are estimated to be in a range of $15.6M-$16M. In addition, cash, cash equivalents and short-term investments totaled approximately $181.9M at March 31, 2015.
16:03 EDTDYAXDyax files to sell 7M shares of common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use